M4MM Generic Letter for Public Comment: Advocacy for Rescheduling Marijuana to Schedule III

Long-form Generic Letter for Public Comment: Support for Rescheduling Marijuana to Schedule III

[Your Name]
[Your Address]
[City, State, ZIP Code]
[Email Address]
[Date]

Drug Enforcement Administration
Attn: DEA Federal Register Representative/DPW
8701 Morrissette Drive
Springfield, Virginia 22152

RE: Docket No. DEA-2024-0059-0001

Dear Sir/Madam,

I am writing to express my support for the rescheduling of marijuana to Schedule III under the Controlled Substances Act, as proposed in the DEA Rescheduling Draft Docket No. DEA-1362; A.G. Order No. 5931-2024. Below are the key reasons for supporting this change:

**Lower Potential for Abuse**
Marijuana has been found to have a lower potential for abuse compared to substances in Schedule I and II. Scientific studies and epidemiological data indicate that marijuana's abuse potential is significantly lower than that of drugs like heroin and cocaine, justifying its placement in Schedule III.

**Accepted Medical Use**
Marijuana has a currently accepted medical use in the United States, as recognized by the Department of Health and Human Services (HHS). It is used in state-authorized medical programs to treat various conditions, such as chronic pain, nausea, and more, demonstrating its therapeutic benefits.

**Safety Under Medical Supervision**
Marijuana has an acceptable safety profile when used under medical supervision. Rescheduling to Schedule III will ensure that necessary regulatory controls are in place, allowing for safe medical use while minimizing risks associated with misuse and abuse.

**Limited Dependence Liability**
The potential for physical and psychological dependence on marijuana is moderate to low. Withdrawal symptoms are generally mild, further supporting the appropriateness of Schedule III classification, where drugs have a lower potential for abuse and dependence compared to Schedules I and II.

**Support from Medical Organizations**
Various professional organizations recognize the therapeutic benefits of marijuana and support its rescheduling to facilitate more research and reduce regulatory barriers. This support underscores the medical community's confidence in marijuana's safety and efficacy.

**Regulatory and Economic Benefits**
Rescheduling marijuana to Schedule III will enable more research and development into its medical uses, potentially leading to new treatments and medications. It will also align with international treaty obligations, ensuring compliance while allowing for domestic regulatory flexibility.

**Conclusion**
Rescheduling marijuana to Schedule III is a scientifically and medically justified step that acknowledges its therapeutic benefits while ensuring proper regulatory oversight. This change will benefit patients, support economic growth, particularly in minority communities, and align with both domestic and international regulatory standards.

I urge the DEA to proceed with rescheduling marijuana to Schedule III to reflect its lower abuse potential and recognized medical use.

Thank you for considering my comments.

Sincerely,

[Your Name]

Members and advocates can use this letter as a template to submit their comments to the DEA Rules Making public comment site at [regulations.gov](http://regulations.gov).
Short-form Concise Generic Letter for Public Comment: Support for Rescheduling Marijuana to Schedule III

[Your Name]
[Your Address]
[City, State, ZIP Code]
[Email Address]
[Date]

Drug Enforcement Administration  
Attn: DEA Federal Register Representative/DPW  
8701 Morrissette Drive  
Springfield, Virginia 22152

RE: Docket No. DEA-2024-0059-0001

Dear Sir/Madam,

I am writing to support the rescheduling of marijuana to Schedule III under the Controlled Substances Act. Here are the main reasons:

**Lower Potential for Abuse**
Marijuana has a lower potential for abuse compared to Schedule I and II substances like heroin and cocaine. Its abuse potential is significantly less, making Schedule III appropriate.

**Medical Use**
Marijuana is recognized for its medical use in treating conditions such as chronic pain and nausea. It meets the criteria for Schedule III, which includes drugs with accepted medical uses and moderate to low abuse potential.

**Safety and Dependence**
Marijuana is safe when used under medical supervision. Its potential for physical and psychological dependence is low, and withdrawal symptoms are mild, supporting its classification in Schedule III.

**Professional Support**
Many medical organizations recognize the benefits of marijuana and support its rescheduling. This reflects the medical community's confidence in its safety and efficacy.

**Regulatory and Economic Benefits**
Rescheduling to Schedule III will facilitate more research into marijuana’s medical uses and ensure compliance with international treaties while allowing for domestic regulatory flexibility.

**Conclusion**
Rescheduling marijuana to Schedule III is justified by its lower abuse potential, recognized medical use, and manageable safety profile. This change will benefit patients and support economic growth, especially in minority communities.

I urge the DEA to proceed with rescheduling marijuana to Schedule III.
Thank you for considering my comments.

Sincerely,

[Your Name]

Members and advocates can use this letter as a template to submit their comments to the DEA Rules Making public comment site at regulations.gov.